Status:
WITHDRAWN
Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
ChiRhoClin, Inc.
Conditions:
Cellular Diagnosis, Pancreatic Cancer
Autoimmune Pancreatitis
Eligibility:
All Genders
19-90 years
Brief Summary
BACKGROUND: Auto immune pancreatitis (AIP), a benign pancreatic disease has certain morphological forms which mimics pancreatic malignancy in radiological appearance. There is no singe diagnostic tes...
Detailed Description
A total of 100 patients with suspicion of Auto Immune Pancreatitis will be identified from the multidisciplinary pancreatic cancer clinic at Johns Hopkins and from the Pancreatitis clinic of the Divis...
Eligibility Criteria
Inclusion
- Male or female \>18 years of age.
- Patients suspected of having AIP based on prior clinical work up
Exclusion
- Unwilling or unable to give written, informed consent.
- Presence of pace makers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
- Patients with acute pancreatitis
Key Trial Info
Start Date :
February 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01845467
Start Date
February 1 2013
End Date
December 1 2018
Last Update
January 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21205